ArticleBiomedical optics express2022
Multiplexed COVID-19 antibody quantification from human sera using label-free nanoplasmonic biosensors.
Article in Biomedical optics express, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 21 citations in OpenAlex.
- Wafer-Scale All-Dielectric Quasi-BIC Metasurfaces: Bridging High-Throughput Deep-UV Lithography with Nanophotonic Applications.Nano letters · 2026Article
- Unlocking the Translational Potential of Nanophotonic Biosensors: Perspectives on Application-Guided Design.ACS photonics · 2025Review
- Surface Relief Gratings of Slide-Ring Hydrogels for Label-Free Biosensing.Gels (Basel, Switzerland) · 2025Article
- Leveraging Optical Anisotropy of the Morpho Butterfly Wing for Quantitative, Stain-Free, and Contact-Free Assessment of Biological Tissue Microstructures.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Introduction to the feature issue: Advances in Optical Biosensors for Biomedical Applications.Biomedical optics express · 2024Article
- Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies.European journal of internal medicine · 2023Review
- Label-free optical biosensors in the pandemic era.Nanophotonics (Berlin, Germany) · 2022Review
- High sensitivity detection of SARS-CoV-2 by an optofluidic hollow eccentric core fiber.Biomedical optics express · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Serological assays that can reveal immune status against COVID-19 play a critical role in informing individual and public healthcare decisions. Currently, antibody tests are performed in central clinical laboratories, limiting broad access to diverse populations. Here we report a multiplexed and label-free nanoplasmonic biosensor that can be deployed for point-of-care antibody profiling. Our optical imaging-based approach can simultaneously quantify antigen-specific antibody response against SARS-CoV-2 spike and nucleocapsid proteins from 50 µL of human sera. To enhance the dynamic range, we employed multivariate data processing and multi-color imaging and achieved a quantification range of 0.1-100 µg/mL. We measured sera from a COVID-19 acute and convalescent (N = 24) patient cohort and negative controls (N = 5) and showed highly sensitive and specific past-infection diagnosis. Our results were benchmarked against an electrochemiluminescence assay and showed good concordance (R∼0.87). Our integrated nanoplasmonic biosensor has the potential to be used in epidemiological sero-profiling and vaccine studies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.